Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01546363 · ClinicalTrials.gov registry record
Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 95
- Enrollment target
NCT01546363: Completed study, sponsored by Stanford University.
NCT01546363 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 95 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01546363 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 95 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cervical cancer patients. We believe that some of these markers may be useful in selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.
Interventions
- OTHER Blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2012-02-24 |
| Est. Completion | 2020-06-29 |
What the finished NCT01546363 record still lists
NCT01546363 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 95 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood draw is the first listed.
NCT01546363 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01546363 about?
NCT01546363 is a clinical study titled "Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer". The purpose of this study is to measure the levels of serum proteins and other biomarkers in cervical cancer patients. We believe that some of these markers may be useful in selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse...
What is the current status of trial NCT01546363?
This trial is currently completed. The enrollment target is 95 participants. The study started on 2012-02-24. Estimated completion is 2020-06-29.
What interventions are being tested in trial NCT01546363?
The interventions under investigation include: Blood draw (OTHER).
Who is sponsoring clinical trial NCT01546363?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI